Not a single study
Story checked
New Obesity Drugs: Latest Pipeline and Research (opens in a new tab)
webmd.com · 2025-02-21
Short answer
Not a single studyNo clear answer.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
New Obesity Drugs: Latest Pipeline and Research
webmd.com · 2025-02-21
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
This story isn't reporting one study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Open claim evidenceSearch result
No single source study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 10Not checkedWeight-loss drugs can help, and people may want to try one if they’re obese or overweight with a condition like type 2 diabetes or high blood pressure.View evidenceHide evidence
As statedabout 10% of your excess weight
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 10Not checkedThe article says new obesity drugs are moving through the research pipeline, including pills and drugs that work differently from current GLP-1 medicines.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 10Not checkedCagriSema combines semaglutide and cagrilintide and is being tested in phase 3 trials for overweight and obesity with and without type 2 diabetes.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 10Not checkedIn a phase 2 study of 92 adults with type 2 diabetes who were overweight or had obesity, CagriSema improved A1c more than semaglutide or cagrilintide alone and led to more weight loss.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 10Not checkedA review of 76 studies with more than 39,000 people found CagriSema led to more weight loss than any other GLP-1 drug, with an average loss of almost 31 pounds.View evidenceHide evidence
As statedalmost 31 pounds
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 10Not checkedEcnoglutide is described as a GLP-1 agonist being studied for overweight, obesity, and type 2 diabetes, with phase 2 and phase 3 results showing improved A1c and weight loss.View evidenceHide evidence
As statedmore than 43% of those who took the 1.2-mg dose had lost 5% or more of their starting weight
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 7 of 10Not checkedMazdutide is described as a GLP-1 and glucagon receptor agonist in phase 3 development, with phase 1 and phase 2 studies showing weight loss and improved blood sugar control.View evidenceHide evidence
As statedabout 6% to 12% in early studies; more than 11% in a phase 2 dose group
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 8 of 10Not checkedRetatrutide is described as a triple-hormone-receptor agonist in phase 3 trials, and early studies showed major weight loss, lower A1c, improved cholesterol and blood pressure, and improvement in MASLD.View evidenceHide evidence
As stated23% to 24% of body weight in the 8 mg and 12 mg groups
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 9 of 10Not checkedSurvodutide is described as a GLP-1 and glucagon agonist in phase 3 studies, with phase 2 studies showing weight loss, better A1c, and improved liver fat in MASH.View evidenceHide evidence
As stated6% to 15% of body weight after 46 weeks
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 10 of 10Not checkedVK2735 is described as a GLP-1 and GIP agonist with promising phase 2 results for weight loss and an oral version in early development.View evidenceHide evidence
As statedup to 15% of their body weight after 13 weeks
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Europe PMC, Crossref · 15 candidate papers
Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy · 2026 · PubMed, Europe PMC
Semaglutide reduces HbA1c and body weight across baseline HbA1c subgroups in the SUSTAIN 1–5 clinical trials
2017 · Crossref
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.
Annals of Medicine and Surgery (2012) · 2026 · PubMed, Europe PMC
Semaglutide reduces HbA1c and body weight across multiple background OAD treatment categories
2017 · Crossref
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.
2026 · Europe PMC
And 10 more candidates considered.